Viral adjuvants

Details Viral adjuvants Viral adjuvants

2011-01-04

2011-01-04

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

Virus

C424S205100, C424S218100, C424S199100, C424S093200

Reexamination Certificate

active

07862829

ABSTRACT:
The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.

REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5505947 (1996-04-01), Johnston et al.
patent: 5639650 (1997-06-01), Johnston et al.
patent: 5643576 (1997-07-01), Johnston et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5789245 (1998-08-01), Dubensky et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5811407 (1998-09-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 5951975 (1999-09-01), Falo, Jr. et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6004807 (1999-12-01), Banchereau et al.
patent: 6008035 (1999-12-01), Johnston et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6015694 (2000-01-01), Dubensky et al.
patent: 6156304 (2000-12-01), Glorioso et al.
patent: 6156558 (2000-12-01), Johnston et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6224879 (2001-05-01), Sjoberg et al.
patent: 6242259 (2001-06-01), Polo et al.
patent: 6277633 (2001-08-01), Olsen
patent: 6376236 (2002-04-01), Dubensky, Jr. et al.
patent: 6468982 (2002-10-01), Weiner et al.
patent: 6521235 (2003-02-01), Johnston et al.
patent: 6521457 (2003-02-01), Olsen
patent: 6531135 (2003-03-01), Johnston et al.
patent: 6541010 (2003-04-01), Johnston et al.
patent: 6583121 (2003-06-01), Johnston et al.
patent: 6783939 (2004-08-01), Olmsted et al.
patent: 6844188 (2005-01-01), MacDonald et al.
patent: 7045335 (2006-05-01), Smith et al.
patent: 2001/0016199 (2001-08-01), Johnston et al.
patent: 2003/0091591 (2003-05-01), Xiong et al.
patent: 2003/0232035 (2003-12-01), Dubensky, Jr. et al.
patent: 2003/0232036 (2003-12-01), Johnston et al.
patent: 2004/0030117 (2004-02-01), Johnston et al.
patent: 2004/0121466 (2004-06-01), Johnston et al.
patent: 2004/0166573 (2004-08-01), Smith et al.
patent: 2004/0208848 (2004-10-01), Smith et al.
patent: 2005/0054107 (2005-03-01), Chulay et al.
patent: 2005/0123555 (2005-06-01), Olmsted et al.
patent: 2006/0099587 (2006-05-01), Johnston et al.
patent: 2006/0177819 (2006-08-01), Smith et al.
patent: 2007/0166820 (2007-07-01), Smith et al.
patent: 0 659 885 (1994-12-01), None
patent: WO 92/10578 (1992-06-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 95/32733 (1995-12-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/21416 (1996-07-01), None
patent: WO 96/37220 (1996-11-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 97/24447 (1997-07-01), None
patent: WO 97/38087 (1997-10-01), None
patent: WO 98/00163 (1998-01-01), None
patent: WO 98/36779 (1998-08-01), None
patent: WO 98/50071 (1998-11-01), None
patent: WO 99/30734 (1999-06-01), None
patent: WO 99/51263 (1999-10-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/39318 (2000-07-01), None
patent: WO 01/16343 (2001-03-01), None
patent: WO 01/47456 (2001-07-01), None
patent: WO 02/20721 (2002-03-01), None
patent: WO 02/099035 (2002-12-01), None
patent: WO 03/083065 (2003-10-01), None
patent: WO 2004/044157 (2004-05-01), None
patent: WO 2007/046869 (2007-04-01), None
Jochim et al (Journal of the American Veterinary Medical Association 165(7): 621-625, 1974 , abstract only cited).
Craig et al (Journal of Immunology 102:1220-1227, 1969).
Howard et al (Journal of Immunology 103:699-707, 1969).
Hruskova et al (Acta Virologica 16:155-124, 1972;( Hruskova A).
Hruskova et al (Acta Virologica 16:125-132, 1972) (Hruskova B).
International Search Report and the Written Opinion of the International Searching Authority for PCT Application No. PCT/US05/24424, mailed Aug. 14, 2007.
Berglund et al.; “Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice,”Vaccine17 (1999) p. 497-507.
Pushko et al.; “Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization Against Heterologous Pathogens in Vivo,”Virology239, (1997) p. 389-401.
Tsiang et al.; “Effects of 5′-Terminal Modifications on the Biological Activity of Defective Interfering RNAs of Sindbis Virus,”Journal of Virology62(1), 1988, p. 47-53.
Balasuriya et al. “Alphavirus Replicon Particles Expressing the Two Major Envelope Proteins of Equine Arteritis Virus Induce High Level Protection Against Challenge with Virulent Virus in Vaccinated Horses”Vaccine20:1609-1617 (2002).
Balasuriya et al. “Expression of the Two Major Envelope Proteins of Equine Arteritis Virus as a Heterodimer is Necessary for Induction of Neutralizing Antibodies in Mice Immunized with Recombinant Venezuelan Equine Encephalitis Virus Replicon Particles”Journal of Virology74(22):10623-10630 (2000).
Barclay et al. “Encapsidation Studies of Poliovirus Subgenomic Replicons”Journal of General Virology279:1725-1734 (1998).
Barrett et al. “Antibody-mediated Early Death in vivo after Infection with Yellow Fever Virus”Journal of General Virology67:2530-2542 (1986).
Berge et al. “Studies on the Virus of Venezuelan Equine Encephalomyelitis,”Journal of Immunology87:509-517 (1961).
Berglund et al. “Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice,”Vaccine17:497-507 (1999).
Berglund et al. “Outcome of Immunization of Cynomolgus Monkeys with Recombinant Semliki Forest Virus Encoding Human Immunodeficiency Virus Type 1 Envelope Protein and Challenge with a High Dose of SHIV-4 Virus”Aids Research and Human Retroviruses13(17):1487-95 (1997).
Bernard et al. “Mutations in the E2 Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan Sulfate Interaction, Low Morbidity, and Rapid Clearance from Blood of Mice”Virology276:93-103 (2000).
Boisgerault et al. “Cross-Priming of T Cell Responses by Synthetic Microspheres Carrying a CD8+T Cell Epitope Requires an Adjuvant Signal”The Journal of Immunology3432-3439 (2005), vol. 174.
Bouvet et al. “Stimulation of local antibody production: parenteral or mucosal vaccination?”Trends in Immunology23(4):209-213 (Apr. 2002).
Bowers et al. “Dendritic Cell Ontogeny,” 28th Forum in Immunology, Medical Research Institute, The Mary Imogene Bassett Hospital, Cooperstown, NY, p. 880-3.
Bredenbeek et al. “Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs”Journal of Virology67(11):6439-6446 (1993).
Brimnes et al. “Influenza Virus-Induced Dendritic Cell Maturation Is Associated with the Induction of Strong T Cell Immunity to a Coadministered, Normally Nonimmunogenic Protein”The Journal of Experimental Medicine198(1):133-144 (Jul. 7, 2003).
Bukreyev et al. “A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs Against a Lethal-Dose Ebola Virus Challenge”Journal of Virology80(5):2267-2279 (2006).
Bukreyev et al. “Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen is Attenuated and Highly Immunogenic in Primates”Journal of Virology79(21):13275-13284 (2005).
Bulychyov et al. “Disease Course in Guinea Pigs After Aerogenous In

Affiliated with

Also associated with

Rating

Viral adjuvants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral adjuvants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral adjuvants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2620448